Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $6.2 million.

  • Ernexa Therapeutics' Liabilities and Shareholders Equity fell 2003.11% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 8425.81%. This contributed to the annual value of $5.3 million for FY2024, which is 8927.58% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Liabilities and Shareholders Equity of $6.2 million as of Q3 2025, which was down 2003.11% from $7.6 million recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $64.7 million for Q2 2021, and its period low was $5.1 million during Q1 2025.
  • Over the past 5 years, Ernexa Therapeutics' median Liabilities and Shareholders Equity value was $24.6 million (recorded in 2022), while the average stood at $29.0 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Liabilities and Shareholders Equity soared by 67946.9% in 2021, and later crashed by 8981.21% in 2025.
  • Over the past 5 years, Ernexa Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $39.4 million in 2021, then crashed by 43.45% to $22.3 million in 2022, then soared by 120.53% to $49.1 million in 2023, then tumbled by 89.28% to $5.3 million in 2024, then rose by 17.14% to $6.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $6.2 million for Q3 2025, versus $7.6 million for Q2 2025 and $5.1 million for Q1 2025.